JP2025505142A - ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態 - Google Patents

ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態 Download PDF

Info

Publication number
JP2025505142A
JP2025505142A JP2024545809A JP2024545809A JP2025505142A JP 2025505142 A JP2025505142 A JP 2025505142A JP 2024545809 A JP2024545809 A JP 2024545809A JP 2024545809 A JP2024545809 A JP 2024545809A JP 2025505142 A JP2025505142 A JP 2025505142A
Authority
JP
Japan
Prior art keywords
crystalline form
xrpd pattern
cukα radiation
crystalline
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505142A5 (enExample
Inventor
ケリー，ロン・シー
チャベス，メアリー
テン，ジン
ペアレント，スティーブン
ルー，バン
ファレル，ロバート・ピー
ハックル，ジェームズ・イー
アフマトビッチ，ミハウ
ウー，ティアン
リード，ダーレン・エル
シャオ，リンユン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2025505142A publication Critical patent/JP2025505142A/ja
Publication of JP2025505142A5 publication Critical patent/JP2025505142A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2024545809A 2022-02-04 2023-02-03 ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態 Pending JP2025505142A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306781P 2022-02-04 2022-02-04
US63/306,781 2022-02-04
PCT/US2023/012252 WO2023150250A1 (en) 2022-02-04 2023-02-03 Crystalline salt and solvate forms of murizatoclax (amg 397)

Publications (2)

Publication Number Publication Date
JP2025505142A true JP2025505142A (ja) 2025-02-21
JP2025505142A5 JP2025505142A5 (enExample) 2026-03-11

Family

ID=86054183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545809A Pending JP2025505142A (ja) 2022-02-04 2023-02-03 ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態

Country Status (7)

Country Link
US (1) US20250122224A1 (enExample)
EP (1) EP4472985A1 (enExample)
JP (1) JP2025505142A (enExample)
AU (1) AU2023215171A1 (enExample)
CA (1) CA3248348A1 (enExample)
MX (1) MX2024009650A (enExample)
WO (1) WO2023150250A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化

Also Published As

Publication number Publication date
AU2023215171A1 (en) 2024-07-04
US20250122224A1 (en) 2025-04-17
EP4472985A1 (en) 2024-12-11
CA3248348A1 (en) 2023-08-10
MX2024009650A (es) 2024-08-14
WO2023150250A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
RU2489435C2 (ru) Полезные фармацевтические соли 7-[(3r,4r) -3-гидрокси-4- гидроксиметил- пирролидин -1- илметил ]- 3,5- дигидро-пирроло [ 3,2-d] пиримидин-4-она
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
CN121866055A (zh) 阿达格拉西布盐的结晶形式
AU2002212249B2 (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CA3261064A1 (en) TREATMENT METHODS FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CZ2015384A3 (cs) Pevné formy Tenofovir alafenamidu
JP2025505142A (ja) ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
US20230121346A1 (en) The salts of a compound and the crystalline forms thereof
JP2023531078A (ja) 化合物の結晶形態
KR20210017070A (ko) 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도
JP2026503096A (ja) リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）のマレイン酸塩の多形
KR20260059498A (ko) 바이사이클릭 헤테로사이클릴 화합물의 신규 염 및 이의 결정형
AU2023307494A1 (en) Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-fluorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof
CA3219303A1 (en) Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2022033471A1 (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
EA050369B1 (ru) Кристаллическая форма трициклического производного соединения, способ его получения и содержащая его фармацевтическая композиция

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226